The University of Pennsylvania’s Gene Therapy Program will partner with Regeneron to explore whether its two-antibody “cocktail” REGEN-COV2 (casirivimab and imdevimab) can prevent COVID-19 infection when delivered as a nasal spray via AAV vectors, using expertise developed by GTP and its director James M. Wilson, MD, PhD . . .

Get GEN Edge Today!

The post Gene Therapy Pioneer, Regeneron Partner on Nasal Spray vs. COVID-19 appeared first on GEN – Genetic Engineering and Biotechnology News.

Source